References
- GassmannPListMSchweitzerASuckerHHydrosols-alternatives for the parenteral application of poorly water soluble drugsEur J Pharm Biopharm19944026472
- MüllerRHJacobsCKayserONanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the futureAdv Drug Deliv Rev200147131911251242
- DolencAKristlJBaumgartnerSPlaninsekOAdvantages of celecoxib nanosuspension formulation and transformation into tabletsInt J Pharm200937612220421219426794
- JinnoJKamadaNMiyakeMEffect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogsJ Control Release20061111/2566416410029
- MüllerRHPetersKNanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction techniqueInt J Pharm19981602229237
- DongYNgWKShenSKimSTanRBHPreparation and characterization of spironolactone nanoparticles by antisolvent precipitationInt J Pharm20093751/2848819481693
- KesisoglouFPanmaiSWuYNanosizing – oral formulation development and biopharmaceutical evaluationAdv Drug Deliv Rev200759763164417601629
- MauludinRMüllerRHKeckCMKinetic solubility and dissolution velocity of rutin nanocrystalsEur J Pharm Sci2009364/550251019130880
- MosharrafMNyströmCThe effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugsInt J Pharm19951221/23547
- WuWNancollasGHA new understanding of the relationship between solubility and particle sizeJ Solution Chem1998276521531
- KippJEThe role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugsInt J Pharm20042841/210912215454302
- NoyesAAWhitneyWRThe rate of solution of solid substances in their own solutionsJ Am Chem Soc18971912930934
- DokoumetzidisAMacherasPA century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification SystemInt J Pharm2006321111116920290
- BabuVRAreefullaSMallikarjunVSolubility and dissolution enhancement: an overviewJ Pharm Res201031141145
- GhoshIBoseSVippaguntaRHarmonFNanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growthInt J Pharm20114091/226026821371540
- KocbekPBaumgartnerSKristlJPreparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugsInt J Pharm20063121/217918616469459
- RaoGCKumarMSMathivananNRaoMENanosuspensions as the most promising approach in nanoparticulate drug delivery systemsPharmazie20045915914964413
- RabinowBENanosuspensions in drug deliveryNat Rev Drug Discov20043978579615340388
- MatteucciMEHotzeMAJohnstonKPWilliamsRODrug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilizationLangmuir200622218951895917014140
- ZhangJYShenZGZhongJPreparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactantsInt J Pharm20063231/215316016828244
- ZhangXXiaQGuNPreparation of all-trans retinoic acid nanosuspensions using a modified precipitation methodDrug Dev Ind Pharm200632785786316908423
- BabaKPudavarHERoyINew method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drugMol Pharm20074228929717266331
- WangFSunJDengYHRelationship between particle size and solubility of coenzyme Q10 nanosuspensionsJ Shenyang Pharm Univ20102712933939
- SunJDengYHMaYLHanJEquilibrium solubility of naked nanocrystals is not related to particle sizeJ Shenyang Pharm Univ20112808585593
- AnkolaDViswanadBBhardwajVRamaraoPKumarMDevelopment of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?Eur J Pharm Biopharm200767236136917452099
- SheridanPLBucktonGStoreyDEThe extent of errors associated with contact angles II. Factors affecting data obtained using a Wilhelmy plate technique for powdersInt J Pharm19941092155171
- AnderbergEKBisratMNyströmCPhysicochemical aspects of drug release. VII. The effect of surfactant concentration and drug particle size on solubility and dissolution rate of felodipine, a sparingly soluble drugInt J Pharm1988471/36777
- HengDCutlerDJChanHKYunJRaperJAWhat is a suitable dissolution method for drug nanoparticles?Pharm Res20082571696170118320295
- Van EerdenbrughBVermantJMartensJASolubility increases associated with crystalline drug nanoparticles: methodologies and significanceMol Pharm201016718581870
- BergstromCAWassvikCMJohanssonKHubatschIPoorly soluble marketed drugs display solvation limited solubilityJ Med Chem200750235858586217929794
- HecqJDeleersMFanaraDVranckxHAmighiKPreparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipineInt J Pharm20052991/216717715996838
- PalamakulaASolimanMKhanMMRegional permeability of coenzyme Q10 in isolated rat gastrointestinal tractsPharmazie200560321221415801676